Resultados de procura - Rudolf Herbst

  • Mostrando 1 - 7 Resultados de 7
Limitar resultados
  1. 1
    Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers

    Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers por Christian D. Sadik, Ewan A. Langan, Ralf Gutzmer, Maria Isabel Fleischer, Carmen Loquai, Lydia Reinhardt, Friedegund Meier, Daniela Göppner, Rudolf Herbst, Detlef Zillikens, Patrick Terheyden

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

    Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma por Lisa Zimmer, Julia Vaübel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan C. Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma

    Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma por Selma Ugurel, Dirk Schadendorf, Kai Horny, Antje Sucker, Sabine Schramm, Jochen Utikal, Claudia Pföhler, Rudolf Herbst, Bastian Schilling, Christian U. Blank, Jürgen C. Becker, Annette Paschen, Lisa Zimmer, Elisabeth Livingstone, Peter A. Horn, Vera Rebmann

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

    Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohor... por Jan‐Malte Placke, Mona Kimmig, Klaus Griewank, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Julia Welzel, Daniel R. Engel, Sophia Kreft, Antje Sucker, Georg Lodde, Frederik Krefting, Ingo Stoffels, Joachim Klode, Alexander Roesch, Lisa Zimmer, Elisabeth Livingstone, Eva Hadaschik, Jürgen C. Becker, Michael Weichenthal, Alpaslan Tasdogan, Dirk Schadendorf, Selma Ugurel

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

    Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients por Teresa Amaral, Felix Kiecker, Sarah Schaefer, Henner Stege, Katharina C. Kaehler, Patrick Terheyden, Anja Gesierich, Ralf Gutzmer, Sebastian Haferkamp, Jochen Uttikal, Carola Berking, David Rafei‐Shamsabadi, Lydia Reinhardt, Friedegund Meier, Ante Karoglan, Christian Posch, Thilo Gambichler, Claudia Pfoehler, Kai Thoms, Julia K. Tietze, Dirk Debus, Rudolf Herbst, Steffen Emmert, Carmen Loquai, Jessica C. Hassel, Frank Meiß, Thomas Tueting, Vanessa Heinrich, Thomas Eigentler, Claus Garbe, Lisa Zimmer

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg

    Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg por Andrea Forschner, Katharina C. Kähler, Martin Gschnell, Ewan A. Langan, Carsten Weishaupt, Frank Meiß, Kai‐Martin Thoms, R.U. Wahl, Daniela Göppner, Marlene Garzarolli, Michael Max Sachse, Max Schlaak, Markus Reitmajer, Ivonne Kellner, Anja Gesierich, Peter Mohr, Friedegund Meier, Imke von Wasielewski, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Patrick Terheyden, Martin Kaatz, Sebastian Haferkamp, Ulrike Leiter, Selma Ugurel, Michael Weichenthal, Carola Berking, Ralf Gutzmer, Dirk Schadendorf, Lena Nanz, Carmen Loquai

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

    Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma por Inês Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, H.K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne Lo, Alexander M. Menzies

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: